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Narcolepsy is a sleep disorder caused by the loss of orexin (hypocretin)-
producing neurons and marked by excessive daytime sleepiness and a
sudden weakening of muscle tone, or cataplexy, often triggered by
strong emotions. In a mouse model for narcolepsy, we previously
demonstrated that serotonin neurons of the dorsal raphe nucleus
(DRN) mediate the suppression of cataplexy-like episodes (CLEs) by
orexin neurons. Using an optogenetic tool, in this paper we show that
the acute activation of DRN serotonin neuron terminals in the amyg-
dala, but not in nuclei involved in regulating rapid eye-movement
sleep and atonia, suppressed CLEs. Not only did stimulating serotonin
nerve terminals reduce amygdala activity, but the chemogenetic in-
hibition of the amygdala using designer receptors exclusively acti-
vated by designer drugs also drastically decreased CLEs, whereas
chemogenetic activation increased them. Moreover, the optogenetic
inhibition of serotonin nerve terminals in the amygdala blocked
the anticataplectic effects of orexin signaling in DRN serotonin
neurons. Taken together, the results suggest that DRN serotonin
neurons, as a downstream target of orexin neurons, inhibit cata-
plexy by reducing the activity of amygdala as a center for
emotional processing.
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Narcolepsy type 1 (narcolepsy with cataplexy) is a debilitatingsleep disorder caused by degenerative loss of neurons pro-
ducing the neuropeptides orexin A and orexin B (orexin neu-
rons) (1–3). Its symptoms can be divided into two independent
pathological phenomena (4, 5). The first phenomenon is dysre-
gulation of nonrapid eye-movement (NREM) sleep onset: the in-
ability to maintain a consolidated awake period that is characterized
by abrupt transitions from wakefulness to NREM sleep. This phe-
nomenon manifests itself clinically as excessive daytime sleepiness
or sleep attacks. The second phenomenon is dysregulation of rapid
eye-movement (REM) sleep onset: the pathological intrusion of
REM sleep or REM atonia at sleep onset or into wakefulness. It is
during these periods that patients may experience hypnagogic hal-
lucinations, sleep paralysis, and cataplexy. Cataplexy manifests as
sudden episodes of muscle weakness without consciousness im-
pairment triggered by strong emotions of positive valence, including
laughter, joking, and delight.
Similarly, mice lacking orexin peptides, orexin neurons, or orexin
receptors recapitulate human narcolepsy type 1 phenotypes to fur-
ther highlight the critical role that orexin signaling plays in the
maintenance of wakefulness (5–7). The mice demonstrate markedly
decreased duration of wakefulness episodes during the dark phase
(i.e., inability to maintain a long awake period, or sleepiness), abrupt
behavioral arrests with muscle atonia that manifest as direct tran-
sitions from wakefulness to REM sleep in electroencephalogram/
electromyogram (EEG/EMG) recordings (i.e., cataplexy), decreased
REM sleep latency, and increased REM sleep time during the
dark phase.
Orexin neurons are distributed within the lateral hypothala-
mus and send projections throughout the brain and spinal cord.
There are particularly dense innervations to nuclei containing
monoaminergic and cholinergic neurons that constitute the as-
cending activating system in the brainstem and the hypothalamus
(5, 6). We previously elucidated two critical efferent pathways of
orexin neurons; serotonin neurons in the dorsal raphe nucleus
(DRN) inhibit cataplexy-like episodes (CLEs), whereas norad-
renergic neurons in the locus coeruleus (LC) stabilize wakeful-
ness episodes (8). In that study, we called direct transitions from
wakefulness to REM sleep shown in EEG/EMG data CLEs, in
reference to Scammell et al. (9), which were nearly equivalent to
murine cataplexy, although the mice were not videotaped to
confirm their immobility during such episodes.
To further clarify the pathophysiology of narcolepsy and regulation
of sleep/wakefulness by orexin neurons, we aimed to identify the
downstream target that mediates the anticataplectic effects of sero-
tonin neurons in the DRN that also send widespread projections
throughout the brain (10–12). Based on evidence using electrophys-
iological, neurochemical, genetic, and neuropharmacological ap-
proaches, DRN serotonin neurons have long been implicated in
promoting wakefulness and suppressing REM sleep (13, 14). Along
with regulating sleep/wakefulness, serotonin in the brain has been
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implicated in various sensorimotor, affective, and cognitive behaviors
(15–18). Therefore, identifying the action site of DRN serotonin
neurons in preventing CLEs can shed additional light on the multiple
functions of the serotonin system.
Results
Optogenetic Activation of Serotonin Neurons in the DRN Suppresses
CLEs in Narcoleptic orexin-ataxin3 Mice. We previously demon-
strated that serotonin neurons of the DRN mediate an anti-
cataplectic action of orexin neurons (8). To further confirm the
physiological importance of orexinergic activation in DRN se-
rotonin neurons, we compared the activity of DRN serotonin
neurons between control and orexin neuron-deficient (orexin-
ataxin3) mice (7) by measuring Fos protein expression. To in-
crease cataplexy, we gave chocolate to the mice beginning at the
onset of the dark phase (19), as shown in Fig. S1. Fos expres-
sion in the tryptophan hydroxylase 2 (TPH2)-positive serotonin
neurons of the DRN after 90 min of chocolate feeding was sig-
nificantly lower in orexin-ataxin3 mice than in control mice (Fig.
1). That result suggests that orexin neurons indeed enhance the
activity of serotonin neurons directly or indirectly, if not both, as
consistent with the role of orexin signaling in DRN serotonin
neurons in inhibiting CLEs.
Knowing that DRN serotonin neurons send projections
throughout the brain (10–12), we aimed to determine the site of
the anticataplectic action of those neurons: that is, the down-
stream targets of DRN serotonin neurons in suppressing CLEs.
To that end, we used channelrhodopsin-2 (ChR2) to activate the
neurons because axonal projections of ChR2-expressing neurons
can be selectively activated at each target site (20). To minimize
light illumination, we used a variant of ChR2—namely, the sta-
bilized step-function opsin (SSFO) (21)—whose activation with a
single blue-light pulse increases the excitability of targeted cells
during depolarization sustained for more than 30 min. Accord-
ingly, we expressed SSFO in serotonin neurons of the DRN by
stereotaxically microinjecting a Cre-inducible adeno-associated
virus (AAV) vector (20) AAV-EF1α-DIO-SSFO-EYFP (DIO:
double-floxed inverted open-reading-frame) in the DRN of
orexin-ataxin3 mice crossed with Sert-Cre mice (22), which ex-
presses Cre recombinase specifically in serotonin neurons (Sert-
Cre;orexin-ataxin3 mice). In those mice, SSFO-EYFP was
expressed in 92.3 ± 3.62% of TPH2+ cells, and 100% of EYFP+
cells were TPH2+ (n = 5), which confirms the targeted expres-
sion of SSFO in serotonin neurons (Fig. 2A).
Next, we analyzed the sleep/wakefulness patterns of the mice. To
increase the frequency of CLE, we gave mice chocolate for the first
4 h of the dark phase (19). We first inserted an optic fiber above the
DRN to stimulate the cell bodies of serotonin neurons. Without op-
togenetic stimulation, Sert-Cre;orexin-ataxin3 mice expressing SSFO
in DRN serotonin neurons exhibited several CLEs during chocolate
feeding (Fig. 2B). The EEG of CLEs was dominated by θ-activity
and closely resembled that of cataplexy-associated states previ-
ously reported (23), which were enriched during murine cataplexy
and distinguished from REM sleep by a larger, highly irregular
amplitude (Fig. S2 A and B). When DRN serotonin neurons
were optogenetically stimulated during the chocolate-feeding pe-
riod by applying blue light (473 nm, 10-ms pulses, 5 Hz, 1 s) every
30 min (Fig. S1A), CLEs were drastically suppressed, whereas the
fragmentation of wakefulness episodes (i.e., reduced duration of
wakefulness episodes) remained unaffected (Fig. 2 B and D). Time
spent in wakefulness, NREM sleep, and REM sleep did not change
considerably (Fig. 2C and Table S1). We also confirmed that the
activation of SSFO indeed elevated the activity of those neurons ex
vivo via loose patch-clamp recordings on DRN slices and in vivo via
measurements of the expression of the Fos protein (Fig. 2 E–G).
We thus optogenetically reproduced the anticataplectic activity of
DRN serotonin neurons that we had previously demonstrated via a
chemogenetic approach using hM3Dq (8, 24), an excitatory de-
signer receptor exclusively activated by designer drugs (DREADD).
Optogenetic Activation of DRN Serotonin Projections in the Amygdala
Suppresses CLEs in orexin-ataxin3 Mice. We optogenetically acti-
vated SSFO-expressing DRN serotonin terminals to identify the
downstream targets of those neurons in suppressing CLEs. When
brain sections of Sert-Cre mice with an AAV-EF1α-DIO-SSFO-
EYFP injection in the DRN were immunostained with an anti-
GFP antibody, we observed EYFP+ nerve fibers of serotonin
neurons in various brain regions, as previously described (10–12).
Among them, nuclei regulating REM sleep and atonia, includ-
ing the ventrolateral periaqueductal gray (vlPAG), laterodorsal
tegmental nucleus (LDTg), and sublaterodorsal nucleus (SLD),
also known as the nucleus pontis oralis, peri-LC α, and sub-
coeruleus (25–29), received relatively dense EYFP+ projections.
We also detected prominent staining in the substantia nigra
compact part (SNc) and amygdala, especially in the basolateral
nucleus of the amygdala (BLA), as shown in Fig. 3A and Fig. S3A
(8). The SNc plays a critical role in controlling movement and
has also been implicated in regulating REM sleep and cataplexy
Fig. 1. Activity of DRN serotonin neurons is reduced in orexin neuron-deficient
orexin-ataxin3mice. (A) Coronal brain sections containing the DRN prepared from
Sert-Cre (Control) or Sert-Cre;orexin-ataxin3 (Orexin-Ataxin3) mice after 90 min of
chocolate feeding at the onset of the dark phase were double-stained with anti-
TPH (green) and anti-Fos (red) antibodies. Regions outlined with dashed lines are
shown at higher magnification. Fos+ TPH2+ cells are indicated by white arrow-
heads. Aq, aqueduct. (Scale bars, 100 μm.) (B) The number of Fos+ TPH2+ cells
(expressed as a percentage of total TPH2+ cells) decreased, whereas the total
number of TPH2+ cells did not change in Sert-Cre;orexin-ataxin3mice (n = 6). Bar
graphs show mean ± SEM, ***P < 0.001, two-tailed Student’s t test.














(30, 31), whereas the amygdala plays an important role in emo-
tional processing (32) and likely involved in cataplexy triggered by
strong emotion (4, 19, 33).
We placed the optic fiber above these areas unilaterally and
optogenetically stimulated serotonin projections individually in Sert-
Cre;orexin-ataxin3 mice with an AAV-EF1α-DIO-SSFO-EYFP in-
jection in the DRN. Stimulating serotonin terminals in REM-
regulating nuclei such as the vlPAG, LDTg, SubC, and SNc did
not change the frequency of CLE or the mean duration of wake-
fulness episodes in the mice during chocolate feeding (Fig. 3B). By
clear contrast, when serotonin terminals in the amygdala, especially
the central amygdala (CeA) and lateral/basolateral amygdala (LA/
BLA), were optogenetically stimulated, CLEs were suppressed al-
most completely, whereas the mean duration of wakefulness epi-
sodes, REM sleep time, and REM sleep latency remained
unchanged (Fig. 3B and Tables S2 and S3).
To confirm that the activation of SSFO at nerve terminals
indeed increased the release of serotonin, we illuminated the
SSFO-expressing DRN serotonin terminals in coronal slices
containing the amygdala and its surrounding areas. Blue-light
stimulation clearly increased the amount of serotonin in the ex-
tracellular solution, thereby suggesting that SSFO activation in
serotonin nerve terminals enhanced the synaptic release of se-
rotonin in the amygdala and its adjacent areas (Fig. 4A).
Because strong emotion often triggers cataplexy, we speculated
that DRN serotonin terminals in the amygdala reduce amygdala
activity as a means of inhibiting CLEs. As expected, the optogenetic
activation of amygdala serotonin terminals significantly reduced Fos
protein expression in both the CeA and LA/BLA (Fig. 4 B and C).
We also examined amygdala activity following the optic stimulation
of SSFO-expressing serotonin neurons in the DRN. The opto-
genetic excitation of cell bodies of those neurons showed signifi-
cantly reduced Fos protein expression in the CeA and LA/BLA
(Fig. 4D), thereby recapitulating the optogenetic stimulation of se-
rotonin projections in the amygdala (Fig. 4C). Such results suggest
that SSFO activation in serotonin nerve terminals indeed increased
the synaptic release of serotonin and inhibited amygdala activity.
Using slice electrophysiology, we also confirmed that serotonin re-
lease from the terminals of DRN neurons indeed inhibits BLA
principal neurons (see, for example, Fig. 6 F and G).
Chemogenetic Manipulations of Amygdala Activity Bidirectionally
Modulate the Occurrence of CLE in orexin-ataxin3 Mice. To further
confirm the importance of the inhibitory action on amygdala activity
in suppressing CLEs, we expressed an inhibitory DREADD in the
amygdala of orexin-ataxin3 mice by bilaterally microinjecting a pair
of AAV vectors: AAV-EF1α-DIO-hM4Di-mCherry and AAV-SynI-
iCre, which expresses codon-improved Cre (iCre) (34) specifically in
neurons. hM4Di is a DREADD receptor that induces neuronal
hyperpolarization upon binding with its ligand, clozapine-N-oxide
(CNO) (24).
Fig. 2. Optogenetic activation of DRN serotonergic neurons inhibits CLEs in orexin-ataxin3 mice. (A) Coronal brain sections containing the DRN prepared
from Sert-Cre;orexin-ataxin3 mice with a targeted injection of AAV-EF1α-DIO-SSFO-EYFP in the DRN were double-stained with anti-TPH (green) and anti-GFP
(red) antibodies. Regions outlined with dashed lines are shown at higher magnification. The position of an optical fiber implant is indicated by a dotted white
line. (B–D) Episode number of and time spent in CLE (B), REM sleep (C), or mean duration of wakefulness episodes (D) during 4 h of chocolate feeding at the
onset of the dark phase (n = 5). CLEs were suppressed by the optogenetic activation of DRN serotonin neurons in Sert-Cre;orexin-ataxin3 mice. *P < 0.05,
**P < 0.01, ***P < 0.001, two-tailed Student’s paired t test. (E) Photostimulation of SSFO (10-ms pulses of 5 Hz for 1 s) expressed in DRN serotonin neurons
increased their firing frequency in the brain slices. A representative trace of loose-patch clamp recording appears on the left and the time course of mean
frequency relative to the baseline rate (3.9 ± 1.9 Hz) on the right (n = 4). **P < 0.01, effect of time, Friedman’s test. (F) Coronal DRN sections were prepared from
Sert-Cre;orexin-ataxin3mice with (SSFO+) or without (SSFO−) the expression of SSFO-EYFP in the DRN after 4 h of chocolate feeding alongwith photostimulation at
the DRN. Slices were then double-stained with anti-TPH (green) and anti-Fos (red) antibodies. Regions outlined with dashed lines are shown at higher magnifi-
cation. Fos+ TPH+ cells are indicated by white arrowheads. (G) The number of Fos-positive TPH2+ cells, expressed as a percentage of total TPH2+ cells, increased with
the activation of SSFO at the DRN (n = 5). Bar graphs show mean ± SEM, ***P < 0.001, two-tailed Student’s t test. (Scale bar, 100 μm.)
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In the amygdala of orexin-ataxin3 mice that received an AAV
microinjection, hM4Di-mCherry was expressed in the vast majority
of the area covering the CeA (98.5 ± 1.0%) and LA/BLA (89.6 ±
5.3%), as estimated by immunostaining with an anti-mCherry an-
tibody (Fig. 5A and Fig. S4D). Immediately before commencing
the dark phase, we administrated saline or CNO intraperitoneally
in orexin-ataxin3 mice expressing hM4Di in the amygdala and
recorded EEG/EMG for the subsequent 12 h without chocolate
feeding, as performed in our previous study (8). Compared with
saline, CNO substantially reduced the frequency of and time spent
in CLEs during the dark phase (Fig. 5B and Table S4). In contrast,
the fragmentation of wakefulness did not improve. Interestingly,
CNO administration did not reduce CLEs in mice with hM4Di-
mCherry expression in the CeA but not in the LA/BLA (81.4 ±
2.5% of CeA, 15.0 ± 6.0% of LA/BLA) (Fig. S3 B and C and Table
S4). Such results suggest that reducing the activity of LA/BLA
might be more critical than that of CeA in suppressing CLEs.
In a complementary experiment, we expressed an excitatory
DREADD, hM3Dq (24), in the amygdala of orexin-ataxin3 mice
to artificially increase amygdala activity. To that end, we bi-
laterally microinjected a pair of AAV vectors: AAV-EF1α-DIO-
hM3Dq-mCherry and AAV-SynI-iCre. In the amygdala of orexin-
ataxin3 mice receiving an AAV microinjection, hM3Dq-mCherry
was expressed in the vast majority of the area covering the CeA
(92.6 ± 4.3%) and LA/BLA (92.0 ± 4.0%), as estimated by
immunostaining with anti-mCherry antibody (Fig. 5C and Fig.
S4D). Compared with saline, CNO administration significantly
increased the frequency of and time spent in CLEs during the
dark phase (Fig. 5D and Table S4), although the EEG of CLE in
mice administered CNO was indistinguishable from that in mice
administered saline (Fig. S2C). In contrast, the fragmentation of
wakefulness was not exacerbated. Therefore, the induction of
CLE could depend on the level of amygdala activity.
Restoring Orexin Receptors in the Amygdala of Ox1r−/−Ox2r−/− Mice
Cannot Suppress CLEs. Because the amygdala weakly expresses
orexin receptors and receives some orexin-positive fibers spo-
radically (35, 36), the direct orexinergic regulation of the
amygdala in preventing CLEs is more parsimonious, which we
did not test in our previous report (8). In response, we examined
whether restoring orexin receptor expression in Ox1r−/−Ox2r−/−
mice blocked CLEs. In the amygdala of Ox1r−/−Ox2r−/−mice that
bilaterally received an AAV microinjection—a mixture of the
recombinant AAV vectors AAV-EF1a-Ox1r-EGFP and AAV-
EF1a-Ox2r-EGFP (8)—orexin receptors were expressed in the
vast majority of the area covering the CeA (85.4 ± 9.5%) and
LA/BLA (93.6 ± 4.2%), as estimated by immunostaining with an
anti-GFP antibody (Fig. S5). However, mice with such restora-
tion have demonstrated frequent CLEs (8) in conditions with or
without chocolate feeding (Table S5). Because those results
suggest that endogenous orexin release in the amygdala cannot
alone prevent CLEs, suppressing cataplexy in orexin-deficient
mice with the ectopic overexpression of orexin peptides in the
amygdala is clinically relevant but perhaps not physiological (37).
Similar to our current findings, results of other studies, including
our own, have shown that orexin neurons regulate the amygdala
indirectly via LC noradrenergic neurons as part of modulating
fear learning (38, 39).
CLE Relapses When DRN Projection to the Amygdala Is Optogenetically
Inhibited in Ox1r−/−Ox2r−/− Mice with OX2R Restoration in DRN
Serotonin Neurons. Finally, we aimed to demonstrate the in-
volvement of the DRN–amygdala pathway in the orexinergic
suppression of CLEs. We previously showed that the selective
Fig. 3. Optogenetic stimulation of DRN serotonin projections in the amygdala inhibits CLEs in orexin-ataxin3 mice. (A) Representative coronal brain sections
of the amygdala, SNc, vlPAG, LDTg, and SLD prepared from Sert-Cre;orexin-ataxin3 mice with targeted injection of AAV-EF1α-DIO-SSFO-EYFP in the DRN.
Samples show relatively dense projections of DRN serotonin neurons and the optical fiber tracks. SSFO-EYFP+ fibers were stained with anti-GFP antibody
(green). Regions denoted by white arrowheads are shown at higher magnification. lPAG, lateral periaqueductal gray; opt, optic tract; scp, superior cerebellar
peduncle; SNR, substantia nigra reticular part. (Scale bars, 100 μm.) (B) Sert-Cre;orexin-ataxin3 mice expressing SSFO in DRN serotonergic neurons were
unilaterally photostimulated in the regions indicated. The graphs show the episode number of and time spent in CLE, as well as mean duration of wakefulness
episodes during a 4-h chocolate-feeding period with (+light) or without (−light) photostimulation (10-ms pulses of 5 Hz for 1 s, delivered every 30 min).
Photostimulation in the amygdala (Amy) specifically inhibited CLEs. n = 5 for the amygdala and vlPAG; n= 4 for the SNc, LDTg, and SLD. Bar graphs show
mean ± SEM, ***P < 0.001, two-tailed Student’s paired t test.














restoration of OX2R expression in DRN serotonergic neurons
suppressed CLEs, but not the fragmentation of wakefulness, in
narcoleptic Ox1r−/−Ox2r−/− mice lacking both orexin receptor
subtypes (8). Therefore, we examined whether the inhibition of
serotonin presynaptic terminals in the amygdala block the anti-
cataplectic effects of OX2R restoration in DRN serotonin neu-
rons. To that end, we expressed the vertebrate short-wavelength
opsin (vSWO5-HT1B) along with OX2R in DRN serotonin neurons
of Ox1r−/−Ox2r−/− mice by microinjecting a mixture of three
recombinant AAV vectors in the DRN: AAV-Pet1-Ox2r-EYFP, AAV-
EF1α-DIO-vSWO5-HT1B-mCherry, and AAV-SynI-iCre. vSWO5-HT1B is
a mouse short-wavelength opsin fused with the C terminus of the
5-HT1B receptor at its own C terminus that induces neuronal in-
hibition by activating Gi/o signaling pathways upon stimulation
with blue light (40). In those mice, OX2R-EYFP was expressed in
81.2 ± 1.13% of TPH2+ cells, and 98.96 ± 1.04% of EYFP+ cells
were TPH2+, whereas vSWO5-HT1B-mCherry was expressed in
83.1 ± 3.89% of TPH2+ cells, and 80.20 ± 5.18% of mCherry+
cells were TPH2+ (n = 7), as shown in Fig. 6A. We also observed
mCherry+ nerve fibers in the amygdala (Fig. 6B).
Without optogenetic stimulation, Ox1r−/−Ox2r−/− mice with
OX2R and vSWO5-HT1B expression in their DRN serotonin
neurons demonstrated few CLEs during the chocolate-feeding
period at the beginning of dark phase, as consistent with the
results of our previous study (8). By clear contrast, bilaterally
applying blue light in the amygdala (473 nm, for 5 min every
30 min) (Fig. S1B) induced numerous CLEs in the same mice
(Fig. 6C and Table S6). Such results suggest that the DRN
serotonin neuron–amygdala pathway is critical in suppress-
ing CLE via orexin neurons.
Fig. 4. SSFO activation in serotonin nerve terminals increases seroto-
nin release and inhibits the activity of amygdala in orexin-ataxin3 mice.
(A) Coronal slices containing the amygdala were photostimulated (5 Hz, 1 s)
at the time indicated by blue columns. Serotonin concentrations in the ex-
tracellular solution are plotted. n = 4 for SSFO(−); n = 5 for SSFO(+). The
pound symbol (#) represents interaction between time and SSFO, P < 0.05,
two-way repeated-measures ANOVA; The asterisk (*) represents SSFO(−)
versus SSFO(+), P < 0.05, Mann–Whitney’s U test. (B) Coronal amygdala sec-
tions were prepared from Sert-Cre;orexin-ataxin3 mice with (SSFO+) or
without (SSFO−) the expression of SSFO-EYFP in DRN serotonin neurons after
4 h of chocolate feeding along with photostimulation at the amygdala. Slices
were then immunostained with anti-Fos (red) antibody. Regions denoted by
white arrowheads are shown at higher magnification. (Scale bars, 100 μm.) (C) The
number of Fos+ cells was reduced in both the CeA and LA/BLA by the optogenetic
activation of DRN serotonin nerve terminals at the amygdala (n = 5). (D) The
number of Fos+ cells was reduced in both the CeA and LA/BLA by the optogenetic
activation of DRN serotonin cell bodies at the DRN (n = 5). Bar graphs show the
mean ± SEM, **P < 0.01, ***P < 0.001, two-tailed Student’s t test.
Fig. 5. Chemogenetic manipulations of amygdala activity bidirectionally
changes the frequency of CLE in orexin-ataxin3 mice. (A and C) Coronal
brain sections of the amygdala prepared from orexin-ataxin3 mice with bi-
lateral injection of AAV-SynI-iCre and AAV-EF1α-DIO-hM4Di-mCherry (A) or
AAV-EF1α-DIO-hM3Dq-mCherry (C) in the amygdala (CeA and LA/BLA) were
stained with anti-mCherry (red) antibody. Regions denoted by white arrowheads
are shown at higher magnification. (Scale bars, 100 μm.) (B andD)Orexin-ataxin3
mice with hM4Di-mCherry (B) or hM3Dq-mCherry (D) expression in the amygdala
were injected with saline or CNO at the onset of the dark phase. The graphs
show episode number of and time spent in CLE; mean duration of wakefulness
episodes during the 12-h dark phase without chocolate feeding are also shown
(n = 7 for hM4Di, n = 4 for hM3Dq). Bar graphs show mean ± SEM, **P < 0.01,
***P < 0.001, two-tailed Student’s paired t test.
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We also confirmed that vSWO5-HT1B stimulation can reduce
serotonin release from the nerve terminals in the amygdala via
electrophysiological recordings and ChR2-assisted transmitter
release in brain slice preparation (Fig. 6 F–H). To do that, we
expressed hChR2(H134R) in serotonin neurons of the DRN
along with vSWO5-HT1B by microinjecting AAV-EF1α-DIO-
vSWO5-HT1B-mCherry and AAV-EF1α-DIO-hChR2(H134R)-EYFP
in Sert-Cre mice. In neurons of the BLA, presumably principal
neurons according to their size, slowly developing hyperpolarization
was evoked by a train of 473-nm light flashes delivered via an optical
fiber placed near the recording area in the presence of gluta-
matergic and GABAergic receptor antagonists (Fig. 6 F and H).
Hyperpolarization was abolished with the application of a 5-HT1A
receptor antagonist, WAY 100635 (30 μM), thereby suggesting that
serotonin was released from the terminal in the amygdala and in-
duced the hyperpolarization via 5-HT1A receptors (Fig. 6G). When
380-nm light illumination preceded the blue-light train to activate
vSWO5-HT1B, blue light-evoked hyperpolarization reduced signifi-
cantly (Fig. 6 F and H). Such results suggest that serotonin release
from DRN neuronal terminals inhibited LA/BLA principal neu-
rons, an action that was reduced by the activation of vSWO5-HT1B in
the terminals.
Discussion
Our study provides additional support for our previous obser-
vations that DRN serotonin neurons mediate the anticataplectic
function of orexin neurons (8). Both studies propose the orexin
neuron–DRN serotonin neuron–amygdala pathway as a critical
circuit to prevent cataplexy.
Absence of Anticataplectic Effects of Serotonin Nerve Stimulations in
Brainstem Nuclei Involved in Regulating REM Sleep and REM Atonia.
Although we failed to suppress CLEs by optogenetically stimu-
lating DRN serotonin neuron terminals in several brain regions
involved in regulating REM sleep and REM atonia, including
the vlPAG, SLD, LDTg, and SNc (25–31), such results do not
completely exclude the contribution of serotonin signaling in
those regions in preventing CLEs. Indeed, we have no means of
knowing whether the conditions of optogenetic stimulations used
in our study were optimal for activating the serotonin projections
of interest. Nevertheless, our results indicate that the amygdala
was the most efficient downstream target of DRN serotonin
neurons in inhibiting CLEs.
The SLD induces atonia during REM sleep by exciting inter-
neurons in the medulla and spinal cord that inhibit motoneurons,
whereas during wakefulness, the SLD is inhibited by neurons in
the vlPAG and adjacent lateral pontine tegmentum (LPT) (25,
27, 28). Containing REM-on cholinergic neurons, the LDTg has
been suggested, albeit not without controversy, to play an im-
portant role in inducing REM sleep and REM atonia by inhibiting
pontine monoaminergic neurons and activating SLD neurons (26,
29). Dopamine neurons in the SNc play a critical role in fine
motor control. They were also implicated in regulating REM sleep
and cataplexy, and modulation of their activity via a D2/D3 agonist
and antagonist aggravated and reduced cataplexy, respectively, in
narcoleptic dogs (30, 31).
Amygdala as the Target Site of DRN Serotonin Neurons in Suppression of
CLEs. In narcoleptic patients, cataplexy is most often triggered by
positive emotions, such as those associated with laughter, joking, or
Fig. 6. Restoration of OX2R in DRN serotonin neurons fails to suppress CLE in Ox1r−/−Ox2r−/− mice when DRN projections in the amygdala are opto-
genetically inhibited. (A) Coronal brain sections containing the DRN prepared from Ox1r−/−Ox2r−/− mice with the targeted injection of AAV-Pet1-Ox2r-EYFP,
AAV-EF1α-DIO-vSWO5-HT1B-mCherry and AAV-SynI-iCre in the DRN were double-stained with anti-TPH (green) and anti-GFP (red) antibodies or anti-TPH
(green) and anti-mCherry (red) antibodies. Regions outlined by dashed lines are shown at higher magnification. (B) Coronal brain sections containing the
amygdala were stained with anti-mCherry antibody (red). The position of an optical fiber implant is indicated by dotted white line. Regions denoted by white
arrowheads are shown at higher magnification. (Scale bars, 100 μm.) (C–E) Episode number of and time spent in CLE (C), REM sleep (D), or mean duration of
wakefulness episodes (E) during 4 h of chocolate feeding at the onset of the dark phase (n = 5). CLE relapsed when blue light was applied (+light) in the
amygdala of Ox1r−/−Ox2r−/− mice expressing OX2R and vSWO5-HT1B in DRN serotonin neurons. **P < 0.01, ***P < 0.001, two-tailed Student’s paired t test.
(F and G) In the amygdala principal neurons, slowly developing hyperpolarization was evoked by the photostimulation of hChR2-expressing serotonin fibers
with a train of 10 473-nm light flashes (10 Hz), each lasting 10 ms, delivered at the timing pointed on the traces (triangle). The photo-evoked hyperpolar-
ization was reduced by a preceding 380-nm light illumination (16 s, shown by a line) 8 s before the 473-nm light train (n = 12 cells) (F) and abolished with the
application of 5-HT1A receptor antagonist, WAY 100635 (30 μM) (n = 2 cells) (G). (H) Summary bars showing changes in the amplitude of the 473-nm light-
evoked hyperpolarization by the preceding 380 nm light. Hyperpolarization was recovered without the 380-nm light (Rec). Bar graphs show mean ± SEM,
***P < 0.001, one-way repeated-measures ANOVA followed by Tukey’s test.














delight (4), as also demonstrated in narcoleptic dogs and mice (6, 7,
19, 41–43). Unsurprisingly, the serotonergic inhibition of the amyg-
dala prevents CLEs, for the amygdala plays an important role in
emotional processing (32), within which LA/BLA subdivisions
form the primary input nuclei and receive processed sensory and
executive information from cortical and subcortical areas. The LA/
BLA consists of glutamatergic principal neurons and GABAergic
interneurons; the former projects to the CeA. The CeA is gener-
ally thought to be an output structure for fear responses (32).
In narcoleptic dogs, a population of sleep-active cells localized
to the CeA and BLA was reported to increase discharges before
and during cataplexy (44). Similarly, in human narcolepsy type
1, amygdala activity increases during cataplexy (45, 46). In an-
other study, all REM-active neurons recorded from the CeA were
inhibited by DRN stimulation in rats (47). Recently, Oishi et al.
demonstrated that Fos expression in the BLA and basomedial
amygdala increases after cataplexy-inducing chocolate feeding
in narcoleptic orexin−/− mice (19). In an accompanying paper,
Burgess et al. reported that excitotoxic lesions of the amygdala
markedly reduced cataplexy in orexin−/− mice without altering basic
sleep/wakefulness (33).
GABAergic CeA neurons send dense innervation to the
vlPAG/LPT, which inhibits REM sleep and maintains waking
muscle tone (33, 48, 49). At the same time, the SLD receives
glutamatergic innervation from the CeA (50–52). Taking these
data together, we find the amygdala is anatomically well posi-
tioned to regulate muscle tone and REM sleep (28).
In the LA/BLA of amygdala slices, serotonin produces a pri-
marily inhibitory response by increasing the GABAergic trans-
mission of interneurons, which subsequently inhibits principal
excitatory neurons (53, 54), and directly hyperpolarizes a mi-
nority of principle neurons (53, 55). We also observed its direct
inhibition in the current study (Fig. 6). Although we did not
discriminate direct and indirect actions of serotonin on the
principal neurons, such electrophysiological findings are consis-
tent with our results that the optogenetic stimulation of seroto-
nin terminals reduces Fos expression in the LA/BLA, where
glutamatergic principal neurons predominate.
As mentioned earlier, cataplexy is usually triggered by positive
emotions, yet rarely by negative ones, such as fear and anxiety
(4). Indeed, studies have shown abnormal amygdala responses to
emotional stimuli in narcolepsy patients, including increased
responses to positive rewards and decreased ones to aversive
stimuli (4, 56–58). Because serotonin transmission in the LA/
BLA participates in the acquisition of cued conditioned fear
(59), we cannot exclude the possibility that the optogenetic
stimulation of serotonin terminals in the LA/BLA suppressed
CLEs by producing fear. In any case, it should be noted that the
involvement of LA/BLA serotonin transmission in the pro-
duction of fear remains controversial (59–65).
Although emotional processing in the amygdala has been
studied extensively regarding the expression and learning of fear,
several lines of evidence have also suggested that it is critically
involved in processing rewarding stimuli (32, 66–73). Different
populations of LA/BLA neurons likely encode fearful or re-
warding information (70, 71, 74, 75). In contrast to the circuit for
fear, output from the LA/BLA mediating positive valence could
be independent of the CeA and depend on its projections to
other brain regions, including the nucleus accumbens (NAc),
which mediates motivated response to reward-predictive cues for
both natural and drug rewards (66, 75). Notably, inhibiting CeA
activity did not reduce CLEs in our study (Fig. S3C). Other re-
search has demonstrated that the activation of LA/BLA 5-HT2A/C
receptors inhibits behaviors related to reward seeking by suppress-
ing the LA/BLA principal neuronal activity (76), and that chocolate
feeding induces Fos in the BLA more than in the CeA of orexin−/−
mice (19). The LA/BLA could thus be a site that plays a critical role
in triggering cataplexy by processing environmental stimuli that
provoke positive emotions.
Orexin neurons respond to drug cues and mediate drug
seeking via projections to the dopaminergic ventral tegmental
area (VTA), as studies with rodents have demonstrated (77–79).
During high reward expectancy, narcolepsy type 1 patients did
not show increased VTA activity as controls did, but instead
exhibited abnormally increased activity in the amygdala (4, 56).
Taken in conjunction with our current results, given rewarding
stimuli, orexin neurons might activate the VTA to increase dopa-
mine efflux. At the same time, orexin neurons could also activate
DRN serotonin neurons to reduce amygdala response. In all, the
amygdala is likely to carry the emotional aspect of rewards.
A Model for How Orexin Neurons Suppress Cataplexy. Because cat-
aplexy and the atonia of REM sleep share many characteristics,
they are likely to be mediated by the same brainstem pathways.
The model derived from previous studies postulates the orex-
inergic augmentation of vlPAG/LPT directly or indirectly, if not
both, via pontine monoaminergic neurons to counterbalance
cataplexy-triggering signals from the CeA, which inhibit the
vlPAG/LPT or stimulate the SLD, if not both (4, 19, 28, 33).
We propose a neuronal pathway by which orexin neurons exert
their anticataplectic action via DRN serotonin neurons by re-
ducing amygdala activity, probably at the LA/BLA (Fig. S6).
Thus, an orexin neuron–DRN serotonin neuron pathway might
inhibit cataplexy by preventing exaggeration of the output of the
amygdala, instead of by directly acting on neurons involved in
regulating muscle tone. That hypothesis is consistent with the
idea that REM sleep and cataplexy are regulated by at least
partially distinct mechanisms, as suggested by previous reports
and the fact that human narcolepsy patients usually remain
conscious during cataplectic attacks (4, 31). Indeed, unlike CLE,
optogenetic stimulations of serotonin terminals in the amygdala did
not improve excessive REM sleep duration, as well as shortened
REM sleep latency in orexin-ataxin3 mice (Table S2). Both our
previous study (8) and another showing no change in REM sleep by
amygdala ablation (33) support that idea.
Technical Considerations. We used a ChR2 variant, SSFO, to
optogenetically stimulate DRN serotonin neurons (21). Unlike
stimulation with conventional ChR2 variants, optical stimulation
of SSFO causes prolonged depolarization and does not pace
neuronal firing (20). As such, the action of SSFO in the nerve
terminals remained unclear. At the opposite extreme, it could
generate a stable increase in calcium that might disrupt the
normal function of the terminals, thereby resulting in a para-
doxical decrease, not increase, of the neurotransmitter release (20).
Nevertheless, we concluded that the SSFO activation enhanced the
presynaptic release of serotonin in the amygdala for three reasons.
First, the activation of SSFO at serotonin fibers in the amygdala
increased the release of serotonin in slices, as observed by direct
measurements of extracellular serotonin. Second, changes in Fos
expression in the amygdala were similar between the SSFO-
mediated activation of serotonin neurons in cell bodies in the
DRN and at the terminals in the amygdala. Third and lastly, SSFO
activates serotonin neuronal terminals in the amygdala and in cell
bodies and suppressed CLEs at both sites.
The photoactivation of one axonal projection using conven-
tional ChR2 would be expected to activate the entire neuron,
including any putative axon collaterals, via a back-propagating
action potential (20). However, the absence of anticataplectic
effects of SSFO activation at serotonin neuronal terminals in the
vlPAG, SLD, LDTg, and SNc made such an effect unlikely.
We have demonstrated the critical role of the DRN–amygdala
pathway in the orexinergic suppression of CLEs by using orexin
receptor-deficient mice with a restoration of OX2R expression
selectively in DRN serotonin neurons (Fig. 6). Therefore, and as
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discussed in our previous study (8), we cannot exclude the pos-
sibility that orexins normally suppress CLEs via additional
pathways independent of the DRN–amygdala pathway, because
we have failed to induce CLEs in wild-type mice by inhibiting
the orexin neuron–DRN serotonin neuron–amygdala pathway.
However, demonstrating that effect would be difficult because
the pathway should be blocked almost completely (<5%) to in-
duce cataplexy, according to Tabuchi et al. (80). Our experi-
ments, the results of which appear in Fig. 6, might overcome such
difficulty because the coinjection of Ox2r-expressing and vSWO-
expressing AAVs was likely to achieve the coexpression of OX2R
and vSWO in a majority of infected cells. Furthermore, the loss-of-
function analyses, including those concerning optogenetic inhibition,
sometimes underestimate the importance of the blocked component
because of compensation or redundancy, if not both. It should be
noted that DRN serotonin neurons are currently the sole direct
targets of orexin neurons identified for the efficient suppression of
CLEs (8). Therefore, our study has substantial scientific importance
in delineating a neuronal circuit for preventing cataplexy.
Materials and Methods
Animals. Orexin-ataxin3, Ox1r−/−Ox2r−/−, and Sert-Cre (provided by Xiaoxi
Zhuang, The University of Chicago, Chicago) mice were described previously
(7, 8, 22). The 12- to 20-wk-old male mice (backcrossed to C57BL/6J) were
used. Mice were maintained under a strict 12-h light/12-h dark cycle in a
temperature- and humidity-controlled room and fed ad libitum. All experi-
mental procedures involving animals were approved by the appropriate
institutional animal care and use committee of Kanazawa University.
Generation of Recombinant AAV Vectors. The plasmid pAAV-EF1α-DIO-SSFO-
EYFP-WPRE-pA was provided by Karl Deisseroth, Stanford University, Stanford,
CA. This plasmid was modified to construct pAAV-EF1α-DIO-vSWO5-HT1B-
mCherry-WPRE-pA by replacing SSFO-EYFP with vSWO5-HT1B-mCherry (40).
The plasmid pAAV-EF1α-DIO-hM4Di-mCherry-WPRE-pA and pAAV-EF1α-DIO-
hM3Dq-mCherry-WPRE-pA were provided by Bryan Roth, University of North
Carolina, Chapel Hill, NC. The plasmid pAAV-SynI-EYFP-WPRE-pA (provided by
Karl Deisseroth) was modified to construct pAAV-SynI-iCre by replacing EYFP
with iCre (34) (provided by Rolf Sprengel, Max-Planck Institute for Medical
Research, Heidelberg, Germany). Recombinant AAV vectors (AAV2-rh10) were
produced using a triple-transfection, helper-free method and purified as de-
scribed previously (81). The titers of recombinant AAV vectors were determined
by quantitative PCR: AAV-EF1α-DIO-SSFO-EYFP, 1.9 × 1013; AAV-EF1a-DIO-
hM4Di-mCherry, 1.1 × 1012; AAV-EF1α-DIO-hM3Dq-mCherry, 4.2 × 1012; AAV-
SynI-iCre, 1.9 × 1013; AAV-EF1α-DIO-vSWO5-HT1B-mCherry, 2.4 × 10
13 genome
copies per milliliter. AAV vectors AAV-Pet1-Ox2r-EYFP-WPRE-pA, AAV-EF1a-
Ox1r-EGFP, AAV-EF1a-Ox2r-EGFP, and AAV-EF1α-DIO-hChR2(H134R)-EYFP were
described previously (8).
Surgery. Implantation of an EEG/EMG electrode, optic fiber, and stereotaxic
injection of AAV vectors were performed as described previously (8); 0.5–1.0 μL of
purified virus was delivered to each site (0.05 μL/min). After 5 min of rest, the
needles were removed. The stereotaxic coordinates of the Hamilton needle sy-
ringe placement were as follows (relative to the bregma): DRN (4.4-mm poste-
rior, 0-mm lateral, 3.0- and 3.5-mm ventral); amygdala (1.6-mmposterior, ±2.5-mm
lateral, 4.5- and 5.2-mm ventral). The stereotaxic coordinates of the tips of op-
tical fiber implants (BFH48-200, Thorlabs) were as follows: DRN (4.4-mm poste-
rior, 0-mm lateral, 3.0-mm ventral); amygdala (1.6-mm posterior, 3.0-mm right,
4.5-mm ventral); SNc (3.0-mm posterior, 0.8-mm right, 4.2-mm ventral); vlPAG
(4.2-mm posterior, 0.5-mm right, 2.5-mm ventral); LDTg (5.2-mm posterior;
0.6-mm right, 3.1-mm ventral); SLD (5.2-mm posterior, 1.0-mm right, 4.0-mm
ventral). Optical fibers were bilaterally implanted for the vSWO5-HT1B experi-
ment. After surgery, all animals were housed individually for a recovery period
of at least 14 d. SSFO(−) control mice were implanted with optical fibers and
EEG/EMG electrodes but were not injected with AAV vectors.
After completing EEG/EMG recordings, we evaluated the expression of
SSFO-EYFP, hM4Di-mCherry, hM3Dq-mCherry, OX2R-EYFP, vSWO5-HT1B-
mCherry, OX1R-EGFP, and OX2R-EGFP as described below in recorded mice,
before scoring the sleep/wake stages to select those with expression in more
than approximately half of the cells of interest.
Feeding with Chocolate. For optogenetic experiments, mice were given milk
chocolate after the recovery period (Hershey’s Kiss; Hershey) along with their
regular chow for 24 h starting at Zeitgeber time (ZT) 12 (dark phase onset;
day 1) (Fig. S1). Four days later (day 5), mice were again fed with chocolate
for 4 h (ZT12–16). On day 9, an EEG/EMG was recorded for 4 h (ZT12–16) as
baseline sleep/wakefulness (−light) from mice fed with chocolate. On day 13,
the EEG/EMG was again recorded for 4 h (ZT12–16) with optogenetic stim-
ulation as described below (+light) from mice fed with chocolate.
Optical Stimulation. Blue light (473 nm) was generated with a DL-473 laser
(RappOptoElectronic) and delivered to the animal via an optical fiber (200 μm
core, 0.22 numerical aperture, Thorlabs; 12–25 mW at the tip of optical fi-
ber). This was coupled to the fiber optic implanted on the animals via a
zirconia sleeve. A pulse generator (Bioresearch center) was used to generate
the light stimulation (10-ms pulses at 5 Hz for 1 s or a 5-min pulse) every
30 min for 4 h.
Sleep Recordings. EEG/EMG recordings were performed for the first 4 h during
the dark phase in optogenetic experiments or for 12 consecutive h in the dark
phase in DREADD experiments. EEG/EMG data were analyzed as previously
described (8), and EEG/EMG signals were scored in wakefulness, NREM sleep,
REM sleep, or cataplexy. For cataplexy, we previously confirmed that direct
transitions from wakefulness (>40 s) to REM sleep (>10 s) in EEG/EMG data
perfectly correlated with episodes of abrupt immobility in video data (8).
Such findings satisfy the criteria of Scammell et al. (9). Because we needed to
analyze many animals, we decided to record only EEG/EMG for the rest of
the mice. Although we believe that the identified episodes were equivalent
to murine cataplexy, we have called the direct transitions from wakefulness
to REM sleep CLEs, in reference to Scammell et al. (9). REM sleep latency was
calculated as the latency from the onset of sleep (i.e., transition from
wakefulness to NREM sleep) to the first episode of REM sleep within the
particular sleep episode. Sleep episodes without REM sleep were excluded
from the calculation of REM sleep latency. A spectral analysis of the EEG was
performed by fast Fourier transform using SleepSign (Kissei Comtec). The
analysis yielded power spectra profiles within a 0- to 20-Hz window with a
1-Hz resolution. Data were standardized by expressing each frequency bin as
a percentage relative to the total power of the same epochs.
Drug Administration. The CNO (C0832, Sigma-Aldrich) was dissolved in saline
to a concentration of 0.5 mg/mL. The CNO or saline was administered to each
mouse intraperitoneally (0.3 mL/30 g body weight) at ZT12, and then EEG/
EMG was recorded for 12 h (ZT12–0) without chocolate feeding. This dose of
CNO has been confirmed to have no off-target effects on sleep and wake-
fulness (8). Each mouse received three saline and three CNO administrations
in an alternating manner at intervals of 1 d after saline administration or 2 d
after CNO administration.
Histological Study. Double immunostaining was performed as described
previously (8). Serial coronal brain sections (30-μm thick) were collected in
four series, one of which was further immunostained. The EYFP and mCherry
fluorescence was completely quenched before immunostaining by treating
sections with 0.3% hydrogen peroxide. Antibodies used included: rabbit
anti-GFP (1:500; Invitrogen); mouse anti-TPH (1:500; Sigma-Aldrich); rabbit
anti-cFos (1:15000; sc-52, Santa Cruz Biotechnology); goat anti-mCherry (1:500;
SICGEN); Alexa Fluor 488-conjugated donkey anti-mouse IgG (1:1,000; Molec-
ular Probes); Alexa Fluor 594-conjugated donkey anti-rabbit IgG (1:1,000;
Molecular Probes). A representative optical section was imaged from each
stained section via a fluorescence microscope (BZ-X710; Keyence), and
fluorescent cells in the images were counted. In evaluating hM4Di-mCherry
or hM3Dq-mCherry expression in the amygdala, it was difficult to count the
number of positive cells because the hM4Di-mCherry and hM3Dq-mCherry
were expressed at a high level driven by a ubiquitous promoter and were
strongly localized in the cell membrane and nerve fibers. Therefore, we
measured the areas containing positive cells within the LA/BLA and CeA to
obtain rough estimates of expression.
Electrophysiological Recording. Three- to 6-wk-old Sert-Cre;orexin-ataxin3
mice were injected in the DRN with AAV-EF1α-DIO-SSFO-EYFP or a mixture
of AAV-EF1α-DIO-hChR2(H134R)-EYFP and AAV-EF1α-DIO-vSWO5-HT1B-mCherry.
After 2–4 wk, the mice were decapitated under deep anesthesia with isoflurane
(Mylan). Brains were extracted and cooled in ice-cold cutting solution consisting
of 87 mM of NaCl, 75 mM of sucrose, 25 mM of NaHCO3, 10 mM of D(+)-glucose,
7 mM of MgCl2, 2.5 mM of KCl, 1.25 mM of NaH2PO4, and 0.5 mM of CaCl2
bubbled with O2 (95%) and CO2 (5%) for the DRN recording. Choline chloride
(125 mM) replaced the NaCl and sucrose for the amygdala recording. Coronal
brain slices (250-μm thick) including the DRN or amygdala were prepared with
a vibratome (VT1200S, Leica) and incubated for 1 h at room temperature in














artificial cerebrospinal fluid (ACSF) containing 125 mM of NaCl, 26 mM
of NaHCO3, 10 mM of D(+)-glucose, 2.5 mMof KCl, 2 mM of CaCl2, and 1 mM of
MgSO4 bubbled with O2 (95%) and CO2 (5%). Spontaneous action potentials of
SSFO–EYFP-expressing neurons were recorded with loose cell-attached modes
at 30 °C kept by perfusion of preheated ACSF. Recording glass electrodes were
filled with ACSF (2–4 MΩ). A combination of EPC10/2 amplifier and Patchmaster
software (HEKA) was used to control membrane voltage, data acquisition, and
the triggering of light pulses. A 470-nm LED device (Rapp OptoElectronic) was
used for SSFO stimulation (35 μW). Before commencing DRN recording, the
slices were illuminated with yellow light (575 nm, 10 mW) for 5 s to inactivate
SSFO and obtain the baseline neuronal activity of the targeted cells. In the
amygdala principal neurons, whole-cell recordings weremadewith the electrodes
(4–5 MΩ) filled with an internal solution containing 125 mM of K-gluconate,
4 mM of NaCl, 10 mM of Hepes, 0.2 mM of EGTA, 2 mM of MgCl2, 4 mM of
ATP, 0.4 mM of GTP, and 10 mM of phosphocreatine (pH 7.3, adjusted with
KOH). Neurons were current-clamped at room temperature in the presence
of bicuculline (10 μM), 6-cyano-7-nitroquinoxaline-2,3-dione disodium (CNQX,
10 μM), and D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5, 30 μM; TOCRIS)
to record light-evoked slow hyperpolarization. For vSWO5-HT1B activation,
brain slices were incubated with the external solution supplemented with
25 μM of 9-cis-retinal, 0.025% (±)-α-tocopherol, 0.2% essentially fatty acid-free
albumin from bovine serum, and 0.1% dimethyl sulfoxide (Sigma). A train of
10 473-nm light flashes (2.5–5.0 mW, 10 Hz), each lasting 10 ms, was delivered
to induce ChR2-assisted serotonin release. vSWO5-HT1B was activated by an
illuminating of 380-nm light (40 μW) for 16 s.
Measurement of Serotonin Release in Slices. Coronal slices (250 μm thick)
containing the amygdala or DRN were prepared under red light, as de-
scribed in the previous section, from Sert-Cre;orexin-ataxin3 mice injected
with AAV-EF1α-DIO-SSFO-EYFP into the DRN. After 1-h incubation at room
temperature in ACSF oxygenated with O2 95% and CO2 5%, the slices were
transferred to a microtube containing 120 μL of ACSF. After 10-min in-
cubation at 30 °C, 70 μL of the supernatant was collected for the measure-
ment. After a brief and gentle wash by adding and discarding 70 μL of ACSF
to the slices, another 70 μL of oxygenated ACSF was added for subsequent
sampling after 10 min of incubation. Samples were collected three times for
baseline, and the slices were then illuminated with blue-light pulses (20 mW,
10 ms, 5 Hz for 1 s). The supernatant was collected three times. Slices were
illuminated once again and sampled three more times. After all sampling,
the serotonin concentration of each sample was measured via HPLC with a
reverse-phase column (PP-ODS, Eicom) and an electrochemical detector
(ECD-300, Eicom) to determine the extracellular levels of serotonin. The
mobile phase consisted of 2.1 mM sodium 1-decansulfonate, 0.1 mM EDTA-
2Na ∕0.1 M phosphate buffer adjusted to pH 5.4, and 2% (vol∕vol) methanol.
To eliminate data from the mice with unsuccessful AAV injections, mice
whose DRN slices did not increase serotonin release by the light illumination
were eliminated in the analyses for the amygdala (two of seven mice). Such
a criterion was used because illumination of light to observe the fluores-
cence of SSFO-EYFP for checking SSFO expression before sampling would
result in undesired activation of SSFO.
Statistics. All results are expressed as the mean ± SEM. Comparisons between
individuals were analyzed by two-tailed Student’s t test, whereas those
within the individuals were analyzed by two-tailed Student’s paired t test.
Welch’s t test was used when the variances of two group means were dif-
ferent. For the slice electrophysiological study, Friedman’s test was performed.
For the measurement of serotonin release, two-way repeated-measures ANOVA,
followed by Mann–Whitney’s U test, was performed.
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Fig. S1. Scheme of chocolate feeding, EEG/EMG recording, and photostimulation protocol. (A) Optogenetic activation of neurons and nerve fibers expressing
SSFO. (B) Optogenetic inhibition of nerve fibers expressing vSWO5-HT1B. Thick horizontal bars represent times of chocolate feeding. On day 9, EEG/EMG was
recorded during 4 h of chocolate feeding without photostimulation. On day 13, EEG/EMG recording was repeated with photostimulation of 10-ms pulses at
5 Hz for 1 s delivered every 30 min (A) or a 5-min pulse delivered every 30 min (B) during 4 h of chocolate feeding. ZT, zeitgeber time.
Fig. S2. Characteristics of EEG/EMG during CLEs. (A) Power spectral analysis of EEG by FFT during CLEs and REM sleep in unstimulated Sert-Cre;orexin-ataxin3
mice with SSFO expression in DRN serotonin neurons and an optic fiber above the DRN but without optogenetic stimulation (n = 5). Panels reflect mean spectra
of five mice. Data are standardized by expressing each frequency bin as a percentage relative to the total power of the same epochs. (B) A typical EEG/EMG
trace during a CLE as described in A. Arrows demarcate onsets and terminations of a CLE. (C) Power spectral analysis of EEG by FFT during CLEs and REM sleep
in either orexin-ataxin3 mice expressing hM3Dq in the amygdala and administered saline or CNO or Ox1r−/−Ox2r−/− mice expressing OX2R and vSWO5-HT1B in
DRN serotonin neurons whose amygdalae were optogenetically stimulated (n = 4, 4, and 5, respectively). Values are mean ± SEM. (D) Typical EEG/EMG traces
during CLEs in mice described in C.
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Fig. S3. Projections of DRN serotonin neurons and effects of chemogenetic inhibition of the CeA on CLEs. (A) Coronal brain sections containing the DRN
prepared from Sert-Cre;orexin-ataxin3 mice with targeted injection of AAV-EF1α-DIO-SSFO-EYFP in the DRN were stained brown with anti-GFP antibody.
Particularly dense staining of EYFP+ fibers was observed in the amygdala, as well as in the SNc. Other REM-regulating nuclei (e.g., vlPAG, LDTg, and SLD) also
receive DRN serotonin projections. Regions denoted by black arrowheads are shown at higher magnification. (Scale bars, 100 μm.) (B and C) Chemogenetic
inhibition of the CeA does not suppress CLEs in orexin-ataxin3 mice. (B) Coronal brain sections of the amygdala prepared from orexin-ataxin3 mice with a
bilateral injection of AAV-SynI-iCre and AAV-EF1α-DIO-hM4Di-mCherry in the amygdala were stained with anti-mCherry (red) antibody. Unlike in mice de-
scribed in Fig. 5A, hM4Di-mCherry was expressed in the CeA but not in the BLA in several mice, because of slight differences in AAV injection sites. Regions
denoted by white arrowheads are shown at higher magnification. (Scale bars, 100 μm.) (C) Orexin-ataxin3 mice with hM4Di-mCherry expression in the CeA
were injected with saline or CNO at the onset of the dark phase. The episode number of and time spent in CLEs, and mean duration of wakefulness episodes
during the 12-h dark phase without chocolate feeding are shown (n = 4). The mice represent a subset different from that with hM4Di expression in both the
CeA and BLA shown in Fig. 5. Bar graphs show mean ± SEM, *P < 0.05, two-tailed Student’s paired t test.
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Fig. S4. Anatomy of immunostained amygdala sections and expression of hM3Dq or hM4Di in orexin-ataxin3 mice receiving an AAV injection in the
amygdala. (A–C) Amygdala sections shown in Figs. 4B, 5 A and C, and 6B and Fig. S3 (Right) are overexposed to show anatomical landmarks (Left). White arrows
indicate the external and intermediate capsules. (Scale bars, 100 μm.) (D) Schematics show the spread of hM3Dq-mCherry or hM4Di-mCherry expression. Different
colored lines represent the four (hM3Dq) or seven (hM4Di) different mice of the orexin-ataxin3 group with an injection of AAV-SynI-iCre and AAV-EF1α-DIO-hM3Dq-
mCherry or AAV-EF1α-DIO-hM4Di-mCherry. Drawings are adapted from a mouse brain atlas (82), and anteroposterior coordinates are relative to bregma.
Fig. S5. Expression of orexin receptors in the amygdala of Ox1r−/−Ox2r−/− mice with restored orexin receptors in the amygdala. (A) Coronal brain sections of
the amygdala prepared from Ox1r−/−Ox2r−/−mice that bilaterally received an AAV microinjection (a mixture of recombinant AAV vectors AAV-EF1a-Ox1r-EGFP
and AAV-EF1a-Ox2r-EGFP) were stained with anti-GFP (green) antibody. Regions denoted by white arrowheads are shown at higher magnification. The
leftmost image is an overexposed section of the second-leftmost image to show anatomical landmarks. (Scale bars, 100 μm.) (B) Schematics show the spread of
orexin receptor expression. Different colored lines represent the three different mice. Drawings are adapted from a mouse brain atlas (82), and anteroposterior
coordinates are relative to bregma.
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Fig. S6. Model of the neural pathway by which orexin neurons prevent cataplexy. In the absence of orexin neurons (type 1 narcolepsy), the amygdala
overresponds to emotional stimuli and sends exaggerated output to induce cataplexy. Orexin neurons activate DRN serotonin neurons, which reduce amygdala
activity and prevent cataplexy.
Table S1. Vigilance state parameters recorded from Sert-Cre;orexin-ataxin3 mice receiving
photostimulation in the DRN
Parameter
DRN SSFO(+) (n = 5) DRN SSFO(−) (n = 5)
−Light +Light −Light +Light
Wakefulness
Total time (min) 164.2 ± 6.0 176.9 ± 6.3 162.6 ± 7.8 148.3 ± 8.0
Episode duration (s) 320.2 ± 20.7 368.4 ± 28.0 310.8 ± 31.3 286.0 ± 21.2
Episode no. 26.0 ± 2.9 23.0 ± 0.9 28.8 ± 1.4 25.6 ± 1.4
NREM sleep
Total time (min) 48.1 ± 6.6 50.4 ± 6.6 49.2 ± 5.1 64.6 ± 8.3
Episode duration (s) 124.0 ± 14.2 129.6 ± 15.4 131.8 ± 17.3 198.0 ± 24.3*
Episode no. 21.4 ± 2.8 22.6 ± 1.4 22.0 ± 1.6 19.4 ± 1.4
REM sleep
Total time (min) 13.9 ± 2.0 10.9 ± 1.5* 12.4 ± 2.6 14.5 ± 1.2
Episode duration (s) 87.1 ± 8.2 96.0 ± 8.5 80.9 ± 3.8 70.9 ± 4.9
Episode no. 8.0 ± 0.9 7.0 ± 1.4 9.0 ± 1.8 7.8 ± 1.1
Latency (s) 120.0 ± 13.2 159.7 ± 23.4 147.8 ± 27.9 223.7 ± 30.0
CLE
Total time (min) 13.8 ± 1.2 1.3 ± 1.1*** 15.9 ± 1.3 12.5 ± 1.4
Episode duration (s) 131.8 ± 11.2 64.5 ± 18.2* 135.0 ± 11.7 110.4 ± 10.8
Episode no. 6.4 ± 0.5 1.2 ± 0.5** 7.2 ± 0.7 6.8 ± 0.4
SSFO(−) represents mice without SSFO expression used to gauge the effect of light elimination. EEG/EMG
during 4 h of chocolate feeding were analyzed. Values are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, two-
tailed Student’s paired t test.
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Table S2. Vigilance state parameters recorded from Sert-Cre;orexin-ataxin3 mice receiving photostimulation at
serotonin fibers in the amygdala or SNc
Parameter
Amygdala SSFO(+) (n = 6) Amygdala SSFO(−) (n = 4) SNc SSFO(+) (n = 4)
−Light +Light −Light +Light −Light +Light
Wakefulness
Total time (min) 173.2 ± 7.9 156.6 ± 13.7 179.6 ± 6.1 154.7 ± 2.3* 190.9 ± 3.5 179.2 ± 10.7
Episode duration (s) 333.5 ± 20.4 355.7 ± 70.2 320.8 ± 33.7 317.3 ± 22.5 345.0 ± 17.6 351.5 ± 29.7
Episode no. 27.8 ± 1.4 24.8 ± 0.9 30.8 ± 2.1 24.5 ± 1.8 27.5 ± 1.9 25.5 ± 1.3
NREM sleep
Total time (min) 46.6 ± 6.3 73.7 ± 12.6* 41.7 ± 4.6 63.2 ± 1.9** 27.6 ± 1.9 39.5 ± 8.1
Episode duration (s) 125.7 ± 16.4 185.0 ± 19.1* 99.5 ± 8.9 189.5 ± 8.9*** 80.8 ± 12.8 117.5 ± 23.8
Episode no. 14.2 ± 0.9 7.8 ± 0.9 25.3 ± 2.1 19.5 ± 1.0 15.3 ± 1.5 13.5 ± 1.2
REM sleep
Total time (min) 9.3 ± 1.6 9.1 ± 1.9 7.2 ± 2.1 10.5 ± 0.9 8.6 ± 1.0 8.6 ± 3.0
Episode duration (s) 69.3 ± 5.7 85.1 ± 5.9 91.2 ± 7.4 89.7 ± 10.2 67.5 ± 4.8 64.6 ± 15.3
Episode no. 7.7 ± 1.1 7.5 ± 0.8 5.0 ± 1.6 7.3 ± 0.5 7.8 ± 0.9 6.8 ± 1.9
Latency (s) 141.6 ± 21.8 184.7 ± 16.9 146.3 ± 14.6 170.0 ± 10.3 100.6 ± 18.0 108.4 ± 35.5
CLE
Total time (min) 11.0 ± 0.8 0.5 ± 0.3*** 11.6 ± 0.8 11.4 ± 2.3 12.9 ± 1.3 12.7 ± 0.9
Episode duration (s) 104.3 ± 11.0 31.3 ± 20.1 103.6 ± 8.5 101.3 ± 19.3 103.0 ± 6.7 114.6 ± 15.3
Episode no. 6.5 ± 0.5 0.3 ± 0.2*** 6.8 ± 0.5 6.8 ± 0.3 7.5 ± 0.6 6.8 ± 0.8
SSFO(−) represents mice without SSFO expression used to gauge the effect of light elimination. EEG/EMG during 4 h of chocolate
feeding was analyzed. Values are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed Student’s paired t test.
Table S3. Vigilance state parameters recorded from Sert-Cre;orexin-ataxin3 mice receiving photostimulation at
serotonin fibers in the vlPAG, LDTg, or SLD
Parameter
vlPAG SSFO(+) (n = 5) LDTg SSFO(+) (n = 4) SLD SSFO(+) (n = 4)
−Light +Light −Light +Light −Light +Light
Wakefulness
Total time (min) 168.8 ± 10.6 165.7 ± 7.9 142.5 ± 14.5 133.3 ± 16.4 150.3 ± 8.9 134.7 ± 8.2*
Episode duration (s) 328.4 ± 27.0 326.4 ± 18.4 289.3 ± 18.0 269.0 ± 17.0 307.5 ± 20.8 285.5 ± 21.8
Episode no. 27.2 ± 1.5 26.0 ± 0.9 27.3 ± 2.5 24.5 ± 1.7 26.8 ± 1.8 27.3 ± 1.3
NREM sleep
Total time (min) 47.0 ± 7.8 54.7 ± 6.6 67.7 ± 12.2 74.4 ± 16.0 63.6 ± 10.4 79.5 ± 9.0**
Episode duration (s) 127.6 ± 16.2 169.8 ± 20.2 208.3 ± 50.9 230.8 ± 51.0 184.3 ± 30.1 220.3 ± 26.5
Episode no. 21.4 ± 1.4 19.2 ± 0.9 20.8 ± 2.3 19.3 ± 1.3 20.3 ± 0.5 21.0 ± 0.7
REM sleep
Total time (min) 9.9 ± 2.4 3.0 ± 1.0 13.6 ± 3.6 14.7 ± 3.4 15.2 ± 1.0 17.2 ± 1.9
Episode duration (s) 82.9 ± 12.2 80.1 ± 7.5 84.8 ± 7.6 94.3 ± 2.1 121.6 ± 4.4 110.5 ± 11.8
Episode no. 7.0 ± 1.3 3.0 ± 1.0 9.3 ± 1.7 9.3 ± 1.9 7.5 ± 0.5 9.5 ± 1.0
Latency (s) 137.9 ± 19.5 167.8 ± 14.7 207.3 ± 42.3 209.6 ± 40.0 189.2 ± 39.4 189.8 ± 13.7
CLE
Total time (min) 14.3 ± 1.9 13.7 ± 1.1 16.3 ± 2.0 17.6 ± 4.0 11.0 ± 1.6 8.6 ± 1.3
Episode duration (s) 125.8 ± 13.4 107.8 ± 6.4 129.4 ± 13.8 161.4 ± 41.0 96.8 ± 7.4 77.1 ± 11.8
Episode no. 6.8 ± 0.5 7.6 ± 0.2 7.5 ± 0.3 6.8 ± 0.5 6.8 ± 0.5 6.8 ± 1.0
SSFO(−) represents mice without SSFO expression used to gauge the effect of light elimination. EEG/EMG during 4 h of chocolate
feeding was analyzed. Values are mean ± SEM, *P < 0.05, **P < 0.01, two-tailed Student’s paired t test.
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Table S4. Vigilance state parameters recorded from orexin-ataxin3mice receiving hM4Di or hM3Dq stimulation in
the amygdala
Parameter
Amygdala hM4Di (n = 7) CeA hM4Di (n = 4) Amygdala hM3Dq (n = 6)
Saline CNO Saline CNO Saline CNO
12-h dark phase
Wakefulness
Total time (min) 380.9 ± 14.0 338.1 ± 11.7** 384.9 ± 7.5 362.5 ± 9.7 408.1 ± 19.4 413.9 ± 8.4
Episode duration (s) 287.1 ± 7.0 282.7 ± 10.4 292.2 ± 3.5 265.8 ± 6.5* 324.7 ± 20.1 339.5 ± 44.9
Episode no. 79.0 ± 3.0 70.0 ± 3.4* 79.3 ± 1.1 80.4 ± 2.5 75.2 ± 5.3 74.9 ± 9.1
NREM sleep
Total time (min) 281.9 ± 15.0 333.1 ± 14.9** 275.9 ± 10.4 301.9 ± 11.4 252.6 ± 19.5 241.5 ± 10.1
Episode duration (s) 217.6 ± 18.0 268.9 ± 21.2* 209.7 ± 9.1 221.6 ± 11.1 212.1 ± 28.5 217.5 ± 20.6
Episode no. 77.4 ± 3.0 73.9 ± 3.3 78.3 ± 1.0 79.8 ± 0.8 71.4 ± 5.4 67.5 ± 9.7
REM sleep
Total time (min) 46.3 ± 2.2 47.7 ± 4.0 47.4 ± 1.0 43.9 ± 1.8 49.2 ± 1.9 41.3 ± 2.0
Episode duration (s) 99.6 ± 3.9 114.8 ± 5.5** 101.5 ± 3.5 104.6 ± 6.8 101.9 ± 4.6 110.6 ± 5.8*
Episode no. 28.0 ± 1.3 25.1 ± 2.1* 28.2 ± 1.4 25.5 ± 1.9 29.3 ± 2.3 22.4 ± 0.3**
Latency () 268.3 ± 26.7 373.7 ± 40.0** 255.5 ± 12.4 286.9 ± 24.5 250.5 ± 31.4 270.6 ± 15.8
CLE
Total time (min) 10.8 ± 1.0 1.1 ± 0.2### 11.8 ± 2.5 11.5 ± 2.7 10.1 ± 1.0 22.5 ± 1.2**
Episode duration (s) 118.4 ± 8.2 102.7 ± 13.2 148.9 ± 10.7 122.2 ± 3.6 119.5 ± 6.2 129.4 ± 6.5
Episode no. 5.5 ± 0.4 0.6 ± 0.1### 5.0 ± 1.3 5.7 ± 1.3 5.0 ± 0.4 10.3 ± 0.3**
4-h dark onset
Wakefulness
Total time (min) 144.6 ± 4.7 97.1 ± 6.7*** 145.6 ± 5.0 121.8 ± 13.0 147.8 ± 6.5 143.5 ± 3.5
Episode duration (s) 303.2 ± 13.8 198.4 ± 7.5** 290.3 ± 10.5 230.3 ± 26.3 305.2 ± 19.1 342.3 ± 68.0
Episode no. 29.1 ± 1.2 29.9 ± 1.5 30.5 ± 1.3 32.3 ± 0.9 29.6 ± 1.8 30.6 ± 4.2
NREM sleep
Total time (min) 75.0 ± 5.4 125.6 ± 8.7** 68.8 ± 6.3 98.4 ± 12.7 68.2 ± 6.5 71.5 ± 3.5
Episode duration (s) 169.1 ± 17.1 254.1 ± 30.3* 144.1 ± 12.9 191.8 ± 21.3 152.4 ± 19.7 179.3 ± 21.9
Episode no. 27.1 ± 1.2 31.6 ± 1.7 28.7 ± 1.2 31.3 ± 0.9 27.6 ± 1.9 25.8 ± 3.9
REM sleep
Total time (min) 15.1 ± 1.6 16.7 ± 3.2 17.2 ± 0.6 13.9 ± 2.2 19.1 ± 0.8 13.0 ± 2.0
Episode duration (s) 97.0 ± 6.0 108.6 ± 8.3 97.3 ± 4.0 92.5 ± 8.9 105.8 ± 6.1 120.5 ± 9.9
Episode no. 9.5 ± 0.9 9.0 ± 1.5 10.8 ± 0.5 9.1 ± 0.9* 11.1 ± 0.7 6.6 ± 0.7*
Latency (s) 211.3 ± 30.2 383.9 ± 69.0* 181.8 ± 24.7 208.9 ± 34.8 185.4 ± 22.9 284.2 ± 33.5
CLE
Total time (min) 5.2 ± 0.4 0.5 ± 0.2*** 8.3 ± 1.8 5.7 ± 1.1 4.9 ± 1.1 11.3 ± 0.9**
Episode duration (s) 114.1 ± 8.3 69.4 ± 22.1* 159.6 ± 14.0 119.1 ± 13.8 105.5 ± 15.0 122.2 ± 12.2
Episode no. 2.8 ± 0.3 0.3 ± 0.1** 3.3 ± 0.9 3.0 ± 0.6 2.7 ± 0.3 5.7 ± 0.4***
EEG/EMG during the 12-h or 4-h period without chocolate feeding after CNO administration at the dark onset was analyzed. Values
are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed Student’s paired t test; ###P < 0.001, Welch’s t test.
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Table S5. Vigilance state parameters recorded from Ox1r−/−Ox2r−/− mice receiving the bilateral
restoration of orexin receptors in the amygdala
Parameter
Amygdala OX1R and OX2R (n = 3)
−Chocolate (4 h) −Chocolate (12 h) +Chocolate (4 h)
Wakefulness
Total time (min) 118.3 ± 9.0 347.8 ± 7.0 170.7 ± 5.4
Episode duration (s) 327.3 ± 43.1 277.6 ± 15.9 397.7 ± 39.9
Episode no. 21.3 ± 1.2 74.7 ± 3.5 25.7 ± 3.5
NREM sleep
Total time (min) 102.9 ± 7.9 321.7 ± 6.1 45.5 ± 7.3
Episode duration (s) 259.0 ± 7.8 249.8 ± 13.9 144.0 ± 29.5
Episode no. 22.7 ± 1.7 76.9 ± 3.6 18.3 ± 2.0
REM sleep
Total time (min) 17.7 ± 2.4 50.5 ± 1.6 8.3 ± 3.0
Episode duration (s) 102.3 ± 2.4 98.2 ± 3.9 88.2 ± 17.6
Episode no. 10.3 ± 1.2 30.9 ± 2.1 5.0 ± 1.2
Latency (s) 327.7 ± 27.4 317.5 ± 25.6 161.0 ± 53.4
CLE
Total time (min) 1.1 ± 1.1 4.7 ± 2.1 14.7 ± 5.6
Episode duration (s) 68.0 ± 68.0 103.4 ± 11.2 150.4 ± 33.4
Episode no. 0.3 ± 0.3 2.6 ± 1.0 7.3 ± 3.3
EEG/EMG during the 4-h or 12-h dark phase without chocolate feeding (-chocolate) or during the 4-h chocolate
feeding at the onset of dark phase (+chocolate) was analyzed.
Table S6. Vigilance state parameters recorded from Ox1r−/−Ox2r−/− mice
receiving the restoration of OX2R in DRN serotonin neurons and vSWO5-HT1B
stimulation at DRN projections in the amygdala
Parameter
Amygdala vSWO (n = 4)
−Light (4 h) +Light (4 h)
Wakefulness
Total time (min) 185.1 ± 5.6. 164.7 ± 5.8**
Episode duration (s) 318.6 ± 16.2 231.7 ± 16.0**
Episode no. 30.4 ± 1.6 38.4 ± 3.1*
NREM sleep
Total time (min) 42.2 ± 4.9 60.2 ± 5.1***
Episode duration (s) 79.0 ± 6.8 108.3 ± 14.0*
Episode no. 31.3 ± 1.6 34.9 ± 2.8
REM sleep
Total time (min) 11.9 ± 0.7 9.2 ± 1.6
Episode duration (s) 95.4 ± 11.9 77.2 ± 5.5
Episode no. 8.0 ± 1.0 6.7 ± 1.0
Latency (s) 117.0 ± 6.2 133.7 ± 21.0
CLE
Total time (min) 0.7 ± 0.4 6.0 ± 0.7**
Episode duration (s) 41.1 ± 26.6 77.3 ± 8.8
Episode no. 0.3 ± 0.2 4.7 ± 0.5***
EEG/EMG during the 4-h chocolate feeding was analyzed. Values are mean ± SEM,
*P < 0.05, **P < 0.01, ***P < 0.001, two-tailed Student’s paired t test.
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